Reply to the Editor:  by Pouly, Julia et al.
outgrowth. So the difference in the expres-
sion profile between our c-kit1 cells and
that detected by Pouly and colleagues1 can-
not be the result of cell processing.
Our findings indicate that c-kit1 cells,
present in right atrial appendages, coexpress
CD105 but are CD452. It is therefore un-
likely that these cells are mast cells because
our data indicate that they are probably car-
diac progenitor cells.
Remco Koninckx, MSc
Karen Hensen, PhD
Jean-Luc Rummens, MD
Marc Hendrikx, MD
Virga Jesse Hospital, Hasselt, Belgium and
University of Hasselt, Diepenbeek, Belgium
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To the Editor:
I write to comment on the editorials by Drs
Sundt1 (April 2008) and Westaby2 (March
2008). Dr Sundt is perceptive but fails to
consider that the observational studies sug-
gesting a danger with aprotinin may have
had bias in the analysis.
At the advisory committee meeting of
the Food and Drug Administration (FDA)
held on September 12, 2007, Dr Mangano
allowed the FDA access to the McSPI
(Multicenter Study of Perioperative Ische-
mia) data set. Whereas Mangano and col-
leagues3 used a propensity score that was
based on likelihood of bleeding, the FDA
reanalysis of these data used stratification
according to risk of adverse outcome. The
FDA analysis showed no increases in rela-
tive risks (RRs) for death (RR 0.91, 95%
confidence interval [CI] 0.54–1.53), heart
failure (RR 1.05, 95% CI 0.75–1.47), myo-
cardial infarction (RR 1.10, 95% CI 0.88—
1.39), or renal dysfunction (RR 1.26, 95%
CI 0.76–2.11) when data from 1222 aproti-
nin-treated patients were compared with
those of 1307 patients who did not receive
the drug.4
At the same FDA meeting, Dr Karkouti,
who used matching of pairs of data, showed
that the inclusion into the model of cardio-
pulmonary bypass variables (time and circu-
latory arrest) and transfusion (.4 units of
red blood cells and fresh-frozen plasma)
removed the statistical effects of aprotinin
on renal function.4 The Toronto data have
never shown any other mortality or morbid-
ity risk. Dr Funary also presented the North
West Consortium analysis, which showed
that any apparent effect of aprotinin on
adverse outcome is lost when red blood
cell transfusion numbers are included as
a confounding variable.5
In the article from Shaw and col-
leagues6 of the Duke University Medical
Center, the populations of patients rec-
eiving aprotinin or e-aminocaproic acid
(EACA) were hugely different. No matter
how clever the statistical modeling, cli-
nicians will recognize that there must be
differences in management and outcome
between a patient with isolated myocardial
ischemia undergoing primary, elective
revascularization (given EACA) and one
undergoing a nonelective reoperation for
heart failure associated with valve pathol-
ogy (who would likely receive aprotinin
in about 70%-80% of cases worldwide).
Despite this, Shaw and colleagues6
Figure 1. Immunofluorescent staining on cells
grown out of cardiac tissue. Cells incubated
with CD45-FITC (A, lower left) and C-kit-phycoer-
ythrin (A, upper right). 4,6-diamino-2-phenylindole
(A and B, upper left) was used to stain nuclei. A,
Outgrown c-kit1 cells do not coexpress CD45
and c-kit. B, Cells are incubated with CD105-
FITC (lower left) and c-kit-phycoerythrin (upper
right); 95% of the cells do express CD105 and
a subpopulation coexpresses c-kit. DAPI, 4,6-dia-
mino-2-phenylindole.
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We thank Koninckx and colleagues for their
comments. As stated in our article, data
were obtained from both endomyocardial bi-
opsies and atrial appendages, and these 2
sampling sites yielded concordant data.
However, themajor difference is thatwe per-
formed in situ detection and characterization
of cells, whereas Koninckx and colleagues
cultured cells for 2 weeks before immunos-
tainings. Such a time interval can change798 The Journal of Thoracic and Cardiothe cell phenotype and delete some cell pop-
ulations thatdonotsurviveunderthesecondi-
tions. The latter phenomenon could explain
why Koninckx and colleagues did not find
any mast cell in their myocardial tissue cul-
tures, whereas it is well established that the
myocardium does contain such cells. Be-
causeaminorcomponentof thec-kit-positive
cells could have represented a subset of cells
different frommast cells, we also tested them
for other markers of stemness (CD105, islet-
1, andMDR1). However, in our hands, these
markers remained negative. The data of
Koninckx and colleagues suggest that after
a period of culture, c-kit-positive cardiac
‘‘stem’’ cells can be identified, but it would
beclinicallyrelevantthat theyprovideaquan-
titative estimate of these cells to assess
whether thisnumberallowsonetoreasonably
envision their use for therapeutic purposes.
Julia Pouly, MD
Patrick Bruneval, MD
Philippe Menasche, MD, PhD
Hopital Europeen Georges Pompidou
Department of Cardiovascular Surgery
Paris, France
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